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Abstract
Background: An important use of data obtained from microarray measurements is the classification of tumor types with
respect to genes that are either up or down regulated in specific cancer types. A number of algorithms have been proposed
to obtain such classifications. These algorithms usually require parameter optimization to obtain accurate results depending
on the type of data. Additionally, it is highly critical to find an optimal set of markers among those up or down regulated
genes that can be clinically utilized to build assays for the diagnosis or to follow progression of specific cancer types. In this
paper, we employ a mixed integer programming based classification algorithm named hyper-box enclosure method (HBE)
for the classification of some cancer types with a minimal set of predictor genes. This optimization based method which is a
user friendly and efficient classifier may allow the clinicians to diagnose and follow progression of certain cancer types.
Methodology/Principal Findings: We apply HBE algorithm to some well known data sets such as leukemia, prostate cancer,
diffuse large B-cell lymphoma (DLBCL), small round blue cell tumors (SRBCT) to find some predictor genes that can be
utilized for diagnosis and prognosis in a robust manner with a high accuracy. Our approach does not require any
modification or parameter optimization for each data set. Additionally, information gain attribute evaluator, relief attribute
evaluator and correlation-based feature selection methods are employed for the gene selection. The results are compared
with those from other studies and biological roles of selected genes in corresponding cancer type are described.
Conclusions/Significance: The performance of our algorithm overall was better than the other algorithms reported in the
literature and classifiers found in WEKA data-mining package. Since it does not require a parameter optimization and it
performs consistently very high prediction rate on different type of data sets, HBE method is an effective and consistent tool
for cancer type prediction with a small number of gene markers.
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Introduction
Microarray technology provides wealth of information on
expression levels of thousand genes that has been used for
diagnostic and prognostic purposes for various types of diseases.
The data obtained from microarray measurements leads to
understanding of genes that are being regulated under the disease
conditions including cancer both in biology and clinical medicine
at the molecular level [1]. Cancer is the most deadly genetic
disease, and it occurs either through acquired mutations or
epigenetic changes that lead to altered gene expressions profile of
cancerous cells. Consequently, microarray technology is employed
to identify up or down regulated genes that play a role on the
specific cancers, activation of oncogenic pathways, and to discover
novel biomarkers for the clinical diagnosis [2]. However, such
approach is an expensive, time-consuming process, and not
practical in terms of clinical application for each patient.
Researchers cannot effectively benefit from the current microarray
technology completely due to limitations of the algorithms being
used for data analysis. Building a set of marker genes with data
classification enable to assess the progression cancer. The number
of genes (features) considered in the analysis of microarray data is
very critical. A very small number of genes usually cannot yield
reliable results, whereas very large number of genes decreases the
information by adding noise [3]. Therefore, it is necessary to find
an optimal set of genes for each cancer type as predictors that help
to classify different labeled cells with high prediction accuracy.
An important characteristics of microarray data is the large
number of genes relative to number of samples. This high
dimensionality in gene space increases the computational
complexity while it usually decreases the accuracy of the
classification. This fact brings the necessity of gene selection by
ranking or gene reduction for the high dimensional gene space.
The relevance of genes in cancer occurrence can be categorized
into three classes: Strongly relevant, weakly relevant and irrelevant
genes [4]. Strongly relevant genes are the ones that have been
shown in cancer cell formation and always needed in the optimal
set, whereas the weak relevant genes are necessary for the optimal
set at some conditions. Therefore it is important to select genes
that are used for the identification of diseases for the following
reasons: 1) making the classification easier by revealing only the
relevant genes 2) improving the classification accuracy 3) reducing
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e14579the dimensionality of the data set [5]. In an effort to choose the
optimal subset of predictor genes, different methods such as
neighborhood analysis [6], bayesian variable selection [7],
principle component analysis [8], genetic evolution of subsets of
expressed sequences (GESSES) [9] are employed.
The effectiveness of the selected gene subset is measured by its
prediction accuracy or error rate in classification. IN microarray
experiments, classification of data is a crucial step for the
prediction of phenotype of cells. Different machine learning
approaches have been employed to analyze microarray data
including k-nearest-neighbors [6,10], artificial neural networks [8],
support vector machines [11–13], maximal margin linear
programming [14], and random forest [15]. However, all of these
algorithms require parameter optimization depending on the
structure of data set. For example, two different parameters must
be used in classification of two different cancer types; therefore, the
optimal parameter values must be found for each data set. Our
approach based on mixed integer programming is highly effective
in different applications such as protein fold type prediction [16]
and drug classification [17–19] without requiring any parameter
optimization.
In this work, we show that a systematic and efficient algorithm,
mixed integer linear programming based hyper-box enclosure
(HBE) approach, can be applied to classification of different cancer
types efficiently. We first introduce and establish a consistent
classification method for different types of microarray data.
Second we provide an optimal set of genes as best diagnostic
indicators for different cancer types that gives the highest accuracy
in classification. Information gain attribute evaluator, relief
attribute evaluator and correlation-based feature selection (CFS)
methods are used for gene selection. We conduct experiments
using 6 well known cancer data sets including leukemia data set
[6], two prostate cancer data sets [20], lymphoma [21], diffuse
large B-cell lymphoma (DLBCL) [22], small round blue cell
tumors (SRBCT) [8]. Moreover, biological interpretation of
selected genes is presented with the explanation of their
relationship to the related cancer types from the experimental
results available in literature.
Results and Discussion
We have selected the most widely used data sets in the literature
for the evaluation of our algorithm. These data sets were obtained
from Keng Ridge Bio-Medical (http://datam.i2r.a-star.edu.sg/
datasets/krbd/) and Artificial Intelligence Laboratory (http://
www.ailab.si/supp/bi-cancer/projections/index.htm) databases
(Table 1). All data sets and scripts to run the proposed classification
approach are provided as Supporting Information S2.
Leukemia, AML-ALL
This data [6] consist of two types of leukemia, acute
lymphoblastic leukemia (ALL), and acute myeloid leukemia
(AML). Each sample was obtained from bone marrow and was
analyzed using Affymetrix microarrays containing 7129 genes.
The training data consists of 38 samples (27 ALL and 11 AML),
and the test data consists of 34 samples (20 ALL and 14 AML).
Table 2 shows the classification accuracies of different algorithms
on this data set. The HBE method classifies all test samples
perfectly, and gives the best leave-one-out (LOOCV) result
(98.61%) together with the logistic regression classifier. RBF
Network and HBE method gives average of 97.43% and 97.14%
accuracy with ten-fold cross validation (10-CV) respectively. As an
additional evaluation, HBE method classifies all test samples
perfectly using 4 genes proposed by Golub et al. [6] and gives a
classification accuracy of 98.57% using ten-fold cross validation.
Tan and Gilbert [23] report 91.18% (10-CV) with 1038 genes
using Bagging and AdaBoost methods. Dettling and Buhlmann
[24] obtained the accuracy of 98.61% (LOOCV) with 3 gene
clusters using aggregated trees method, where gene clusters are
reported as a minimum number of 1 and maximum number of 23.
Nguyen and Rocke [25] correctly classifies 33 out of 34 with 50
genes using partial least squares (PLS) and Logistic Discrimination
(LD) classification. Lee et al. [26] misclassifies one sample in test
using 5 genes. Deutsch [9] uses an iterative algorithm to obtain
high classification accuracy with minimum number of genes. Test
samples are classified with an average dimension of 9. Antonov
et al. [14] could predict all samples in test set and obtained the
accuracy of 98% (LOOCV) using 132 genes. Chen et al. [27],
obtained perfect test set accuracy with minimum 7 genes.
Consideration of all these results shows that HBE method is the
most accurate classifier on leukemia data set considering all
validation methods including test set validation, ten-fold cross
validation and leave-one-out validation.
All the genes that have been selected by HBE method are also
selected by Lee et al in their significant gene pool that consists of 27
genes that include redundant genes. Table 3 shows the genes
overlapping with the selected genes by other groups. The highest
accuracy is obtained with the optimal gene set consisting of 4
genes: Myeloperoxidase (M19507-at), adipsin (M84526-at), CD33
antigen and TCF3 transcription factor 3. In fact, previous
experimental and clinical studies indicated that these genes are
associated with Leukemia. Myeloperoxidase is a peroxidase
enzyme that produces hypochlorous acid from hydrogen peroxide
and chloride anion. In recent years, myeloperoxidase staining is
used in the diagnosis of acute myeloid leukemia to show that the
Table 1. Cancer data sets used in this study.
Data set Samples Genes Classes Reference
Leukemia 72 7129 2 Golub et al. (1999)
Prostate cancer 102 12600 2 Singh et al. (2002)
Prostate
outcome
21 12600 2 Singh et al. (2002)
DLBCL 77 7129 2 Shipp et al. (2002)
Lymphoma 47 4026 2 Alizadeh et al. (2000)
SRBCT 83 2308 4 Khan et al. (2001)
doi:10.1371/journal.pone.0014579.t001
Table 2. Classification results of leukemia (AML-ALL) data set.
Classifier Test Set 10-CV LOOCV
HBE 100 97.1460.903 98.61
BayesNet 94.12 95.71 95.83
LibSVM 58.82 86.57610.44 91.67
SMO 97.06 93.1460.571 94.44
Logistic Regression 91.18 96.8661.67 98.61
RBF Network 97.06 97.43±1.07 97.22
IBk 97.06 96.0061.40 95.83
J48 94.12 89.1461.94 90.28
Random Forest 94.12 93.1461.07 90.2
doi:10.1371/journal.pone.0014579.t002
Tumor Classification
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results are in agreement with Chen et al. [27] where myeloper-
oxidase was also selected. Additionally, Chu et al. [29] also selects
MPO myeloperoxide. The membrane antigen CD33 is a sialic
acid-dependent cell adhesion molecule is a membrane protein.
CD33 is highly expressed on the surface of leukaemic blasts. About
85%–90% of acute AML cases are considered to be CD33 positive
[30]. CD33 is constitutively expressed in haematopoietic progen-
itors, but at significantly lower membrane density than in
leukaemia cells [31]. Therefore, CD33 represents an interesting
target for antibody-based anti-leukaemic therapies. This gene is
also selected as an important gene in significant gene subset studies
conducted by other researchers [29,32,33]. Transcription factor 3
(TCF3) plays an important role with tissue-specific basic helix-
loop-helix (bHLH) in embryogenesis [34]. The TCF3-HLF fusion
transcription factor generated by t(17;19)(q22;p13) translocation is
found in a small subset of pro-B cell acute ALL and promotes
leukemogenesis by substituting for the antiapoptotic function of
cytokines [35]. Also it has been shown that TCF3 level is up-
regulated in ALL patients due to this translocation. Additionally,
this protein is the cause of forms of pre-B-cell acute lymphoblastic
leukemia [36]. Also, [29] et al. also selects this gene as one of the
biomarkers in 14 significant gene subset. Although adipsine is a
serine protease homolog which is synthesized and secreted by
adipose cells and is found in the bloodstream has been shown to
plays a role in myeloid cell differentiation [37]. Sakhinia et al. [38]
indicated that gene expression is up-regulated in acute AML
patients by real time PCR. Additionally [29] et al. also selects this
gene as a biomarker.
Prostate Cancer
The prostate cancer data consists of 102 tissue samples (52
prostate tumor and 50 normal tissues) with 12,600 genes.
Considering the results given in Table 4, HBE method is the
most accurate classifier among others with LOOCV (96.08%
accuracy) and it is the second most accurate classifier with
Bayesnet at an average of 94.80% accuracy with ten-fold cross
validation (10-CV). The support vector machines method SMO
reports an average of 95.20% accuracy with 10-CV. Tan and
Gilbert [23] report 75.53% (10-CV) with 2071 genes using
Bagging method. Hewett and Kijsanayothin [33] obtain the
accuracy of 91.18% (10-CV) with 6 genes using SVM on prostate
cancer data set. Statnikov et al. [11] obtain 92% (10-CV) accuracy
without any gene selection. Dettling and Buhlmann [24] report
95.10% (LOOCV) with 3 gene clusters (clusters consist of
minimum 1 gene and maximum 17 genes) using nearest neighbor
method. Similarly, Fort and Lambert-Lacroix [39] get 95.10%
(LOOCV) with 1000 genes using Ridge PLS method. Xiong and
Chen [40] choose Nf most discriminatory genes where Nf takes
values between 10 and 2000. They repeated the experiment 100
times for each Nf value and obtained an average value of 94.78%
using uncorrelated linear discriminant analysis. Finally, Zhang and
Deng [41] report an accuracy of 96.08% (LOOCV) using SVM
with 13 genes.
The selected genes by HBE are serine protease hepsin (X07732),
nel-related protein 2 (D83018), ao89h09.x1 (AI207842), Cdk-
inhibitor p57KIP2 (U22398), DKFZp564I1663-r1 (AL036744),
adipsin/complement factor D (M84526), glutathione transferase 4
(GSTM4) (M96233), DKFZp586K1220 (AL050152), aldose reduc-
tase (X15414), ADP/ATP translocase (J03592). In fact, many of the
genes that have been selected in this study shown to display different
expression patterns in prostate cancer tissues. For example hepsin (a
cell surface serine protease) is significantly upregulated in human
prostate cancer and it promotes cancer progression and metastasis
of prostate [42]. It is reported that the expression of p57Kip2 is
dramatically decreased in human prostate cancer and the
overexpression of p57Kip highly suppresses the cell proliferation
[43]. Furthermore, another selected gene glutathione transferase
mediates the proliferation of androgen-independent prostate cancer
cells [44]. Finally, it has been shown that aldose reductase gene is
responsible in carbohydrate metabolism that converts glucose to
sorbitol [45].
Prostate Cancer Outcome
This data contains 8 patients having relapsed and 13 patients
having non-relapse with measurements of 12600 genes.
Table 5 summarizes the classification results for the of prostate
cancer outcome data set. We performed leave-one-out-validation
Table 3. Selected genes which overlap with genes selected
by other groups (Leukemia data set).
Gene Reference
Myeloperoxide [27], [26], [67], [14]
CD33 [26], [67], [5], [32], [6], [61]
TCF3 [26], [67], [61], [68]
Adipsin [26], [67], [61], [68]
doi:10.1371/journal.pone.0014579.t003
Table 4. Classification results of prostate cancer data set.
Classifier 10-CV LOOCV
HBE 94.8060.4 96.08
BayesNet 94.8061.17 95.10
LibSVM 94.6061.36 95.10
SMO 95.20±0.4 95.10
Logistic Regression 90.0061.10 92.16
RBF Network 93.2060.75 93.14
IBk 93.4061.74 93.14
J48 88.0061.095 90.20
Random Forest 92.6060.49 94.12
doi:10.1371/journal.pone.0014579.t004
Table 5. Classification results of prostate cancer outcome
data set.
Classifier LOOCV
HBE 95.24
BayesNet 95.24
LibSVM 61.90
SMO 57.14
Logistic Regression 47.62
RBF Network 95.24
IBk 80.95
J48 85.71
Random Forest 90.48
doi:10.1371/journal.pone.0014579.t005
Tumor Classification
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HBE method is one of the top classifiers together with BayesNet
and RBF Network with the accuracy of 95.24% compared with
other methods. Tan and Gilbert [23] report 85.71% (10-CV) using
Bagging method with 208 genes. Comparing to the results of Tan
and Gilbert [23], HBE method gives an accuracy of 90% with ten-
fold cross validation using only three genes.
The genes, selected with HBE are shown to play a critical role
in prostate cancers, are human cofactor A protein (AF038952),
farnesyl-protein transferase beta-subunit (HUMFPTB), glutamine-
fructose-6-phosphate amidotransferase (GFAT) (M90516). The
function of heterodimeric enzyme farnesyl: protein transferase
(FPTase) 3 is to transfer of a 15-carbon isoprenoid moiety to a C-
terminal cysteine of many cellular proteins. The inhibition of
farnesyl protein transferase affects for the prevention of proper
functioning of the Ras protein that leads to oncogenesis or cancer.
In fact, elimination of cancer were reported to increase when
prostate cancer cell line is treated with farnesyl-protein transferase
inhibitor [46]. Glutamine:fructose-6-phosphate amidotransferase
(GFA), the first and rate-limiting enzyme in the hexosamine
biosynthetic pathway, transfers the amide group from glutamine to
fructose-6-phosphate to form glucosamine-6-phosphate (GlcN-6-
P), a precursor of uridine diphosphate-N-acetyl-glucosamine. It
has been demonstrated that overexpression of GFA in Rat-1
fibroblasts causes insulin resistance [47].
The diffuse large B-cell lymphoma (DLBCL)
This data set contains 58 samples from DLBCL patients and 19
samples from follicular lymphoma. The gene expression profiles
were analyzed using Affymetrix human 6800 oligonucleotide
arrays. HBE method is the most accurate classifier among the
classifiers with both 10-CV and LOOCV in the DLBCL data set
(Table 6). From the literature, GESSES method predicts all
samples correctly with different random numbers of starting top
genes (from 77 to 130) [9]. The final predictors ranged in number
of genes, from four to twelve. Statnikov et al. [11] reaches the
accuracy of 97.50 (10-CV) without gene selection. Zhang and
Deng (2007) report a classification accuracy of 92.71% (LOOCV)
using kNN (k=5) with 8 genes.
HBE analysis resulted in high classification accuracy with 6
genes which are DNA replication licensing factor CDC47
homolog (D55716-at), gamma-interferon-inducible protein IP-30
precursor (J03909-at), LDHA lactate dehydrogenase A (X02152-
at), CD69 antigen (Z30426-at), SLC (AB002409-at), Rad2
(HG4074-HT4344-at). When the function of those proteins and
their role in DLBCL were analyzed, we see that these proteins play
a significant role in the progression of DLBCL. DNA replication
licensing factor CDC47 is a factor that helps the DNA to undergo
a single round of replication per cell cycle. CDC47 is not only
necessary for DNA replication and cell proliferation, but also for
S-phase checkpoint activation upon UV-induced damage [48].
The function of LDHA lactate dehydrogenase is to catalyze the
conversion of L-lactate and NAD to pyruvate and NADH in the
last step of anaerobic glycolysis. It is proved that mutations in
lactate dehydrogenase A gene causes the exertional myoglobinuria
[49]. CD69, known as early T cell activation antigen, is expressed
on a variety of immune cells, including T- and B- lymphocytes,
NK cells, monocytes/macrophages, and granulocytes [50].
Secondary lymphoid-tissue chemokine (SLC) is a cytokine
belonging to the CC chemokine family and it is constitutively
expressed in a variety of lymphoid tissues. This gene is a potent
and specific chemoattractant for lymphocytes [51]. Rad 2 (Flap
endonuclease 1) is a member of the XPG/RAD2 endonuclease
family and is involved in DNA repair [52].
Lymphoma
The lymphoma data set contains 47 samples, 24 of them are
referred to as germinal center B-like group and 23 are activated B-
like group. This data set contains expression of 4026 genes.
In the lymphoma data set, HBE method is the most accurate
classifier using both ten-fold-cross-validation and leave-one-out
cross validation with the accuracies of 96.40% and 97.87%
respectively (Table 7). Support vector machine algorithm, SMO, is
the second highest accurate classifier with the accuracy of 96.00%
with both of the validation methods. Hewett and Kijsanayothin
[33] have obtained a classification accuracy of 97.87% (10-CV)
with SVM and Bayesian network methods. Dettling and
Buhlmann [24] reports an the accuracy of 100% (LOOCV) with
10 gene clusters (min: 1 and max: 16 of genes) using nearest
neighbor method. The best accuracy reported is in the literature
including this presented paper, Zhang and Deng [41] with 100%
accuracy (LOOCV) using SVM with 3 genes. However, the
specific information of those genes were not reported.
algorithm selects the following genes: Deoxycytidylate deami-
nase (19408), lymphoid-restricted membrane protein (JAW1)
(16886), PKU-beta=KIAA0137=protein kinase (20423), T-cell
protein-tyrosine phosphatase (17140), TTG-2 Rhombotin-2
(19238), stress-activated protein kinase (JNK3) (19384), and
unknown labeled genes with ids 19288, 19274, 13394. Expression
of the following genes are currently being used as markers for
lymphoma in clinical diagnosis. Deoxycytidylate deaminase
(dCMPase) hydrolyzes dCMP into dUMP, and it is suggested
Table 6. Classification results of DLBCL.
Classifier 10-CV LOOCV
HBE 92.25±1.46 96.10
BayesNet 89.060.94 89.61
LibSVM 83.560.94 84.42
SMO 88.2561.0 89.61
Logistic Regression 87.7561.46 89.61
RBF Network 90.561.5 93.51
IBk 87.560.79 88.31
J48 88.2561 89.61
Random Forest 89.7562.15 89.61
doi:10.1371/journal.pone.0014579.t006
Table 7. Classification results of Lymphoma.
Classifier 10-CV LOOCV
HBE 96.40±1.5 97.87
BayesNet 95.2060.98 93.62
LibSVM 94.460.8 93.62
SMO 96.00 95.75
Logistic Regression 92.462.65 91.49
RBF Network 95.2060.98 95.75
IBk 95.261.6 95.75
J48 81.662.33 87.23
Random Forest 92.0061.79 89.36
doi:10.1371/journal.pone.0014579.t007
Tumor Classification
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malignancies [53]. Jaw1, also known as lymphoid-restricted
membrane protein (LRMP), is an endoplasmic reticulum-associ-
ated protein. It is known that the expression of Jaw1/LRMP
mRNA is high in germinal center B-cells and in diffuse large B-cell
lymphomas of ‘germinal center’ subtype [54]. In addition, the
following genes were selected and their expression patterns were
reported to be greatly changed in lymphoma. Among these genes,
PKU-beta, a serine/threonine protein kinase, has role in
chromatin remodeling, DNA replication and mitosis [55]. T-cell
protein tyrosine phosphatases, phospho tyrosine-specific protein
phosphatase, nuclear dephosphorylation of phospho-STAT6
(pSTAT6) was observed in activated-B-cell (ABC)-like tumors.
Moreover, TTG-2 Rhombotin-2 is a cysteine rich protein with
LIM motif and immunohistologic analysis show that LMO2
protein is expressed as a nuclear marker in normal germinal-center
(GC) B cells and GC-derived B-cell lines and in a subset of GC-
derived B-cell lymphomas [56]. Finally, stress-activated protein
Jun N-terminal kinase (JNK3) is a member of mitogen-activated
protein kinase (MAPK) superfamily and it plays an important role
in signaling pathways of critical physiological processes, including
apoptosis, differentiation and proliferation. It is known that the
activation of JNK leads to the interferon-alpha-induced apoptosis
in B-cell lymphoma [57].
Small round blue cell tumors
There are four different small round blue cell tumors in this data
set: Ewing family tumor (EWS), Burkitt lymphoma (BL),
neuroblastoma (NB) and rhabdomysarcoma (RMS). The training
set contains 63 samples and the test set contains 20 samples. The
cDNA microarrays comprise 2308 genes. Small round blue cell
tumors (SRBCT) of childhood are diagnosed using single layer
neural network [8] where the number of genes in the data set was
reduced to 96 to predict the classes of the test data perfectly.
Table 8 shows that HBE method outperforms other classifiers
using all validation methods. It gives perfect classification on the test
set with 5 genes. Moreover, it has an average of 97.5% of accuracy
using ten-fold-cross validation and 96.39% with leave-one-out-cross
validation. Comparing to other studies in the literature, Dettling
and Buhlmann [24] has obtained 100% (LOOCV) with 1 gene
cluster (minimum: 1 gene maximum: 14 genes) using nearest
neighbor method. Deutsch [9] predicts all test samples when 100
predictors were used, where the average number of genes in a
predictor was 12.7. Statnikov et al. [11] obtain perfect accuracy
using ten-fold-cross validation with many methods without gene
selection. Finally, Chen et al. [52] perfectly classifies all samples in
the test set using 10 genes with SVM and kernel Fisher discriminant
analysis. Considering these studies, HBE method is the most robust
method, since it has highest accuracy with the least number of genes
on not onlytest setbutalsousingothertypesof validations including
ten-fold and leave-one-out cross validation.
The selected genes with their gene ids in SRBCT classification
are Fc fragment of IgG, receptor, transporter, alpha (FCGRT)
(70394), transmembrane protein (812105), fibroblast growth factor
receptor 4 (784224), ESTs (295985), recoverin (383188). FCGRT
encodes a receptor binding the Fc region of monomeric
immunoglobulin G. This protein both helps to transfer of
immunoglobulin G antibodies from mother to fetus across the
placenta, and binds to immunoglobulin G to prevent the antibody
degradation [58]. Growth factor receptors (FGFRs) bind fibroblast
growth factors which play key roles in proliferation and
differentiation of different type of cells and tissues [59]. Recoverin
is neuronal calcium-binding protein that plays a role in the
inhibition of rhodopsinosopsin kinase which is a regulator in the
phosphorylation of rhosopsin [60]. Zhoua et al. [61] also select
FCGRT, transmembrane protein, ESTs, recoverin in their
significant gene pool (Table 9). Chen et al. [27] selects FCGRT
and fibroblast growth factor receptor 4.
Conclusion
Thecontributionsofthisworkaretwo-fold.Thefirstcontribution
is that we implement an effective optimization based classifier that
gives very high performance and valuable insight into different type
of cancer data sets. Previously it has been shown that our approach
was successfully applied to protein folding and drug classification
problems. HBE approach does not require parameters to optimize
in order to obtain high classification accuracies. This method canbe
used for different types of data without any modifications. The
second contribution is finding of optimal predictor genes that give
the highest accuracy in classification. This effort can provide to
develop antibody assays for the diagnosis of specific types of cancer
and to provide accurate diagnostics by only measuring expression of
fewgenes.Wehaveappliedouralgorithm onpubliclyavailabledata
sets including leukemia data set, two prostate cancer data sets, two
lymphoma data sets and SRBCT data set. In conclusion, mixed-
integer programming based hyper-box enclosureapproach is robust
and effective method for microarray analysis.
Methods
Preprocessing and Gene Selection
We performed scaling to all data sets by using the expression of
ai~
Ai ðÞ {mini’ Ai ’ ðÞ fg
maxi’ Ai ’ ðÞ fg {mini’ Ai ’ ðÞ fg
ð1Þ
Table 8. Classification results of SRBCT.
Classifier Test Set 10-CV LOOCV
HBE 100 97.5±2.5 96.39
BayesNet 85 94.561.5 95.18
LibSVM 90 84.7560.94 84.34
SMO 95 89.563.22 93,98
Logistic Regression 80 91.561.66 91.57
RBF Network 90 93.2561.0 93.98
IBk 90 92.2560.5 92.77
J48 90 88.7560.79 91.57
Random Forest 95 89.7561.66 92.77
doi:10.1371/journal.pone.0014579.t008
Table 9. Selected genes which overlap with genes selected
by other groups (SRBCT data set).
Gene Reference
FCGRT [27], [61]
Transmembrane protein [61]
Fibroblast growth factor receptor [27]
ESTs [61]
Recoverin [61]
doi:10.1371/journal.pone.0014579.t009
Tumor Classification
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maxi’fA(i’)g and mini’fA(i’)g are the maximum and minimum
gene expression levels respectively. Additionally, in cross validation
runs, the data was randomly divided into k-fold.
There are generally three types of approaches in feature (gene)
selection: Filters, wrappers, and feature weighting. Filter methods
eliminate irrelevant features according to some prior knowledge.
Wrapper approaches use machine learning algorithms to evaluate
the feature subsets; however, they have high computational
complexity when they combined with classification algorithms.
Feature weighting methods simply weigh features instead of
selecting a subset of features that is a combinatorial problem. We
employed information gain attribute evaluator, relief attribute
evaluator, and correlation-based feature selection (CFS) from Weka
machine learning package [62] for the gene selection. The details of
these algorithms can be found in the work of Wang et al. [5].
Information gain evaluates a feature (gene) by measuring the
information gain with respect to the class:
H(Y)~{
X
y[Y
p(y)log2 (p(y)) ð2Þ
where Y and X are the features, p(y) is the marginal probability
density function for random variable Y. Equation 1 provides the
entropy of Y. Entropy is a measure of uncertainty in information
theory. There is a relationship between feature X and Y when
following cases are ensured: i) expression values of feature Y in the
training set are partitioned in due to the expression values of
second feature X ii) the entropy of Y prior to partitioning is higher
than the entropy of Y with respect to the partitions induced by X.
The entropy of Y after observing X is given in Equation 2.
HY jX ðÞ ~{
X
x[X
p(x)
X
y[Y
py jx ðÞ log2 (py jx ðÞ ) ð3Þ
InfoGain~H(Y){HY jX ðÞ ð4Þ
where p(yjx) is the conditional probability of y given x.
Information Gain (Equation 3) is a measure of additional
information about Y provided by X representing the amount by
which the entropy of Y decreases.
Relief attribute evaluator is an evaluating algorithm that rates
features (genes in our case) due to these facts: (1) how well their
values distinguish among samples of different classes (tumor type in
our case) (2) how well they cluster instances of the same class [63].
Correlation-based feature selection (CFS) is a fast algorithm that
reveals a good feature subset that contains features highly
correlated with the class, yet uncorrelated with each other [64].
CFSS~
krcf ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
kzkk {1 ðÞ rff
p ð5Þ
where CFSS is the score of a feature subset S containing k
features, rcf is the average feature to class correlation (f [S), and
rff is the average feature to feature correlation. The numerator of
Equation 4 indicates how predictive of the class a group of features
are and the denominator is a measure of redundancy among that
group of features.
Classification: Hyper-box enclosure algorithm
The objective in data classification is to assign samples that are
described by several attributes into a predefined number of classes.
In this study, we propose HBE algorithm for the classification of
cancer types. This algorithm consists of integer programming (IP)
and mixed integer linear programming (MILP) based components,
and the data points belonging to different classes are discriminated
by hyper-boxes. The use of hyper-boxes for defining boundaries of
the sets that include all or some of the samples in that set can be
very accurate on both two-class (normal/cancer) and multi-class
(more than two tumor types) problems. If it is necessary, more than
one hyper-box could be used in order to represent a class. When
two classes are both represented with a single hyper-box
respectively, the boundaries of these hyper-boxes may overlap.
Thus, two boxes could be constructed in order to eliminate this
overlapping. The description of the optimization model is given in
Supporting Information S1.
Figure 1 summarize the steps of hyper-box enclosure algorithm.
Also, an illustrative example explaining the HBE algorithm is
given in Figure 2. In the illustrative example, the problem consists
of two attributes and four classes (Figure 2a). First, the maximum
and the minimum attribute values are calculated for each class
(Figure 2b). Then, the boundaries of the classes are compared to
check whether they overlap. If the boundaries of the classes
overlap, then the samples that are enclosed by other classes are
identified (Figure 2c). These samples are called as ‘problematic’
samples, since they are not separable from the samples of the other
classes with a single hyper-box. In the case of having large number
of ‘problematic’ samples, the same procedure is repeated to reduce
the total number of such samples. In some cases, applying one or
Figure 1. The flowchart of the algorithm.
doi:10.1371/journal.pone.0014579.g001
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problematic samples as desired; therefore we use integer
programming based seed finding algorithm to reduce this
computational complexity.
Seed Finding
This step is used to improve the computational efficiency by
determining representative seeds for each class (Figure 2d). Seed
finding is a method that selects a representative sample (seed) for
each class (tumor type) and fixes assignments of these samples to
their respective classes before solving the problem. The seeds
improve the computational performance of the model without
changing the optimal solution. The determination of seeds is a
critical task: the seeds for each class must be chosen to ensure that
seeds are separated well from each other as well as being a good
example of the group of samples in the same class. We develop a
pure integer programming (IP) formulation to accomplish this task.
Samples are represented by the parameter aim that denotes the
value of attribute m for the samples i. The class k of sample i
belongs to is given by the set Dik. Moreover, PPii’ represents the
distance between two samples i and i’. This distance is calculated
using Euclidean distance in m dimensional space as given in
Equation (5).
As it is proven in Uney-Yuksektepe [65], the constraint set of the
seed finding model has the totally unimodular property. This
property theoretically guarantee that every basic feasible solution
of the LP relaxation of seed finding model defined by constraint (8)
is integer. Therefore, optimal solution of LP-relaxation is the
optimal solution of Seed Finding model which means that solution
of Seed Finding model could be easily obtained in very short time.
Hence, determination of seeds is not a major undertaking due to
this theoretical property. For example, the Seed Finding model is
solved in 0.063 seconds for classification of leukemia. Moreover,
seed finding algorithm optimally determines the corresponding
seed for each class. Hence, for a given data set exactly the same
instances will be selected as seeds for distinct runs of seed finding
model.
Furthermore, different classification models will always develop
different models (rules, trees, boxes, etc.) for different data sets. In
classification problems, benchmark data sets are used in order to
compare the results of different methods. As the same benchmark
data sets for each tumor problem are used to compare distinct
models, the comparisons are unbiased and stable for this study.
For instance, the most popular data classification method Support
Vector Machines (SVM) will produce different hyper-planes for
perturbations in the original data set. Hence, differences between
the constructed hyper-boxes of different data sets are not an
interesting and problematic issue for data classification.
PPii’~
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ X
m
aim{ai’m ðÞ
2
r
ð6Þ
min z~
X
k
X
i[k
X
i’[k
PPii’YPi{
1
card i[k ðÞ
  
  (
X
k
X
i[k
X
i’= [k
PPii’YPi) ð7Þ
X
i[k
YPi~1 ð8Þ
The objective of the IP-Seed problem given in Equation (6) is to
minimize the distances from each seed to sample of its group (in-
class distances) and maximize the average distances from each seed
to the samples that belong to other classes (out-class distances).
Equation (7) states that every class must have exactly one seed, and
integrality of the decision variable YPi is given by YPi [0,1.
Figure 2. The illustrative two dimensional classification problem. a) The two-dimensional four-classes illustrative example. Each color
represents one class. b) The determination of boundaries for corresponding classes for all samples. c) The determination of problematic samples. d)
The identification of representative samples (seeds) from each class using pure IP. e) Construction of hyper-boxes for problematic samples using
MILP. f) Construction of hyper-boxes for non-problematic samples.
doi:10.1371/journal.pone.0014579.g002
ð7Þ
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Training part studies are performed on a training data set
composed of a number of samples i. The samples are represented
by the parameter aim that denotes the value of gene m for the
sample i. The class k that the sample i belongs to are given by the
set Dik. Each existing hyper-box l encloses a number of samples
belonging to the class k. Moreover, bounds n (lower, upper) of
each hyper-box is determined by solving the training problem (the
mathematical model is granted in Additional file 1).
Minimization of the number of misclassified samples in the data
set with the minimum number of hyper-boxes is the objective of
the mixed integer linear programming model. The objective
function is
min z~
X
i
X
k
ypikz
X
k
ybl ð9Þ
where ypik indicates the misclassification of sample i to class k and
the existence of hyper-box l is represented by binary variable ybl.
The lower and upper bounds of the hyper-boxes are determined
by the samples that are enclosed within the hyper-boxes. Hence,
lower and upper bounds of hyper-boxes are calculated by related
constraints. Moreover, the bounds of hyper-boxes exist if and only
if this hyper-box is assigned to a class. There exist constraints that
ensure the assignment of each data point to a single box and single
class [66]. It is also shown in Figure 2e.
Intersection elimination
Since the MILP model is solved for ‘problematic samples’ only,
the ‘non-problematic samples’ are assigned to hyper-boxes in a
straight forward manner (Figure 2f). We define k hyper-boxes for
each class and assign a ‘non-problematic sample’ to corresponding
newly defined hyper-box. Each ‘non-problematic sample’ is
considered one by one until all of these samples are assigned to
a hyper-box. Finally, the bounds of these new hyper-boxes are
determined by considering the maximum and minimum attribute
values of all samples in these hyper-boxes. It may be possible that
the constructed hyper-boxes obtained from MILP model and
defined hyper-boxes have intersections. Samples are separated
from the defined hyper-box until all intersections are eliminated.
The eliminated instances are grouped in a new box and
intersection checking and elimination procedure is repeated until
no more intersections occur between all of the constructed and
defined hyper-boxes (Figure 3).
Optimal Gene Set Finding
After the initial gene ranking, the optimal gene set is searched
by using F cumulative distribution function (FCDF) and the
classification iteratively. FCDF is computed at each values in X
using the corresponding parameters in v1 and v1. FCDF is:
p~F(xjv1,v2)~
ð C
v1zv2 ðÞ
2
  
C
v1
2
  
C
v2
2
   (
v1
v2
)
v1=2 t
v1{2 ðÞ =2
½1z
v1
v2
  
t 
v1zv2 ðÞ =2 dtð10Þ
where p is the probability that single observation from an F
distribution with parameters v1 and v2. In our case, v1 is the
number of samples and v2 is number of samples at each class. X is
the division of the variances of each gene of all samples to the
variances of each gene of each sample. As a result p value for one
class is calculated 1- FCDF. While defining the relatively irrelevant
genes (the least informative genes) to leave the model within the
optimal gene subset the gene with the maximum p value for one of
the classes is selected. In this way, the least informative gene that is
indicated by very low p value (close to 0) for that particular class is
replaced by the most informative gene that has a value (close to 1)
for that particular class. As the least and most informative genes
were calculated by FCDF, the least informative genes are replaced
by the most informative ones, and hyper-box enclosure method is
used at each iteration. The set giving the highest classification
accuracy is reported as the optimal gene set. Also, the genes whose
ranking scores are the highest are checked whether there is a
redundancy among them by considering the pair correlation-
coefficients. As a result, this approach selects the most relevant
genes to the target classes and minimizes the redundancy among
the selected genes to define an optimal gene set which provides the
highest classification accuracy.
Supporting Information
Supporting Information S1 MILP formulation of the hyper-
box enclosure approach.
Found at: doi:10.1371/journal.pone.0014579.s001 (0.05 MB
PDF)
Supporting Information S2 Source codes, scripts and data
files.
Found at: doi:10.1371/journal.pone.0014579.s002 (0.78 MB ZIP)
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